Background: The aim of this study was to determine the clinical activity and toxicity of a novel chemotherapy combination regimen of gemcitabine plus cisplatin, administered every three weeks, in patients with advanced non-small-cell lung cancer (NSCLC).
Introduction
Patients with advanced non-small-cell lung cancer (NSCLC) have a poor prognosis regardless of treatment strategy. Chemotherapy, with or without radiotherapy, has been shown to improve survival and the quality of life of these patients [1] . A recently published metaanalysis evaluated the impact of combination chemotherapy on survival in advanced NSCLC, showing a benefit for chemotherapy with an absolute increase in the survival rate [2] .
Gemcitabine (2',2'-difluorodeoxycytidine) is a new nucleoside antimetabolite analog of deoxycitidine that has demonstrated activity in different preclinical solid tumor models [3] [4] [5] . Phase II trials of gemcitabine as single agent in previously untreated patients with NSCLC have shown response rates of 20% to 26% [6] . Synergism between gemcitabine and cisplatin was demonstrated in preclinical and clinical studies, with non-overlapping toxicity [7] .
Previous phase II studies with cisplatin and gemcitabine have used a four-week schedule [9] [10] [11] [12] [13] . Grade 3-4 thrombocytopenia occurred in more than 50% of the patients, which forced omission or reduction of the third dose of gemcitabine, causing a considerable reduction in the final dose-intensity delivered of this drug. Based on these data, we performed a phase II study with a novel schedule of gemcitabine (1250 mg/m 2 , days 1 and 8), plus cisplatin (100 mg/m 2 , day 1), administered every three weeks.
Patients and methods
Included were 26 consecutive chemotherapy-naive patients with histologically-confirmed NSCLC stage Illa/b or IV measurable disease with performance status 0 to 2 on the Zubrod scale, and adequate bone marrow, liver, and renal function. Pretreatment evaluation included a complete history and physical examination, chest X-ray, and chest/ abdominal CT scans.
One course of treatment consisted of the administration of gemcitabine on days 1 and 8 at a dose of 1250 mg/m 2 with cisplatin 100 mg/m 2 given immediately thereafter on day 1. Cycles were repeated every 21 days.
Response to therapy was assessed by standard WHO criteria. Toxicity was documented according to NCIC-CTC grade. Dose intensity was calculated in mg/m 2 /week as described by Hryniuk [8] .
Results
The patient characteristics are listed in Table 1 . Of 25 assessable patients, one achieved a CR and 16a PR. The overall response rate was 65.3% (95% CI: 45%-82%). Responses were observed at all stages: partial responses occurred in four of five stage Ilia, seven of nine stage Illb, and five of 12 stage IV. One stage 1Kb patient attained a CR, and died three months following treatment of an acute myocardial infarction. Fifteen patients received additional treatment (radiotherapy or surgery). Relief of the symptoms was observed in most of the patients during treatment: dyspnea (53.8%), cough (46.2%), pain (38.5%), and hemoptysis (38.5%). This was usually observed within the first two cycles.
At last evaluation, disease progression had occurred in five patients (one stage Illb and four stage IV). With a median follow-up of 10 months, 17 patients remain alive and nine have died (five of tumor progression, one of myocardial infarction, one of pulmonary thromboembolysm, and one of post-surgery respiratory distress). The estimated median overall survival was 12 months.
A total number of 117 cycles was administered, with each patient undergoing a median of four chemotherapy cycles (range: 1-7). Two-hundred four (87%) full doses of gemcitabine, of a potential 234, were administered. Twenty-four doses were reduced and six omitted due to neutropenia or thrombocytopenia. The median dose-intensity of chemotherapy administered was: 715 mg/m 2 /week for gemcitabine, and 31 mg/m 2 /week for cisplatin (86% and 94% of the planned dose, respectively).
The most significant toxicity was hematological. Grade 3 neutropenia developed in 46.2%, and grade 4 in 7.7% of the patients. Neutropenia was characterized by a deep but short-lived nadir at mid-cycle. Three episodes of fever (grade 2) resolved following therapy with oral antibiotics. One patient had grade 4 febrile neutropenia and required intravenous antibiotics. Thrombocytopenia grade 3 was documented in five (19.2%) patients and grade 4 in one (3.8%). Grade 3 anemia occurred in two patients (7.7%).
The non-hematological toxicity included: nausea and vomiting NCIC-CTC grade 2-3 in 10 patients (38.4%). Three patients presented grade 2 neurotoxicity. Other toxic effects were (% of patients with worst toxicity): flu-like symptoms (19.2%), lethargy and malaise (34.6%) and peripheral edema (15.4%). Grade 2 skin-rash was seen in three patients.
Discussion
The current phase II study demonstrated a high antitumoral activity of a novel gemcitabine and cisplatin regimen in previously untreated NSCLC patients, with a response rate of 65.3%. The regimen was demonstrated to be safe and well tolerated. Toxicity was mild, and did not require major modifications of the treatment. Scheduling and, to some extent, exposure to cisplatin and gemcitabine appeared to be important factors for drug interaction. In vitro or in vivo simultaneous administration was as effective as sequential administration considering the antitumor activity, but toxicity was enhanced when both drugs were administered on schedules with four-hour intervals. The rationale for weekly dosing of gemcitabine is based on preclinical data showing that the rate of cytarabine phosphorylation by deoxicytidine kinase becomes saturated when the concentration of the nucleoside is raised several-fold above the km-value [3] .
Several promising gemcitabine and cisplatin regimens have been proven in different phase I/II trials (listed in Table 2 ). Shepherd et al. undertook a phase I trial of a four-week cycle of gemcitabine and cisplatin given in combination weekly x3 with a one-week rest [9] . At the recommended dose for phase II trials, gemcitabine 1500 mg/m 2 and cisplatin 30 mg/m 2 , grade 3-4 granulocytopenia was observed in 58% of the patients and grade 3-4 thrombocytopenia in 100%.
In two South African and French-Scottish phase II studies [10, 11] , cisplatin was administered on day 15 to increase the intensity of the gemcitabine dose. However, in the study by Abratt et al. [10] this maneuver resulted in a low cisplatin dose-intensity during the first two cycles (21 mg/m 2 /week). In another phase II study [12] , Crino et al. observed an overall response rate of 54%, with a median survival of 14 months. These results probably also reflect the large proportion of patients with PS 0-1 or locally advanced disease, and the fact that in responding patients treatment could be continued for more than five cycles with gemcitabine alone until disease progression. Toxicity was quite similar to that observed with the aforementioned regimens.
Our objective was to increase dose-intensity of both drugs and to shorten the treatment duration. We preferred to administer cisplatin on day 1, hoping to avoid dose reduction or delays and thereby to maintain the dose intensity of the most active drug in NSCLC.
The response rate (63.8%) in this study is encouraging although it should be interpreted with caution due to the small number of patients and the increased per- centage of stage III (54%) patients included. Nevertheless, a recent phase III study by the Spanish Lung Cancer Group (GECP) [14] , compared this same gemcitabine and cisplatin regimen with an etoposide and cisplatin combination and confirmed its high response rate (48% vs. 22%, respectively).
This novel combination of gemcitabine and cisplatin administered every three weeks is well tolerated and induces a remarkably high response rate. The threeweek schedule of this regimen, as opposed to the previously published four-week schedules, may be particularly attractive for patients who are candidates for local therapy.
